European Pharmaceutical Review

JANUARY 23, 2025

1 all revenue in big pharma now come from dealmaking, confirming a need for robust inorganic growth and value creation strategies The year began with this forecast holding true, as the pharmaceutical industry declared major M&A deals including Johnson & Johnsons acquisition of Intra-Cellular Therapies, Inc. trillion Firepower.

Pharma 59

Pharma Food and Drug Administration Pharmaceutical Government 59

Pharmaceutical Technology

NOVEMBER 8, 2022

Viatris has signed definitive agreements to acquire Oyster Point Pharma and Famy Life Sciences in a deal totalling nearly $700m-$750m in cash to establish an ophthalmology franchise. Oyster Point Pharma introduced Tyrvaya, a nasal spray approved by the Food and Drug Administration (FDA) to treat dry eye disease, in November last year.

Food and Drug Administration 59

Food and Drug Administration Leads Food Pharma 59

European Pharmaceutical Review

MAY 2, 2023

Astellas Pharma has agreed to acquire ophthalmology biotech company Iveric Bio, Inc. The acquisition “seems to be the biggest” in the company ‘s history, Prashant Khadayate, Pharma Analyst at GlobalData observed. billion in 2028, according to GlobalData’s Pharma Intelligence Center. for approximately $5.9

Food and Drug Administration 52

Food and Drug Administration Pharma Sales FDA 52

Pharmaceutical Technology

SEPTEMBER 2, 2022

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration 59

Food and Drug Administration Sales FDA Marketing 59

Pharmaceutical Technology

JULY 12, 2022

The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

Leads 52

Leads Food and Drug Administration Marketing Sales 52